BioSpace News Archive

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the company will present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21st at 1:40 p.m. ET.

Veteran IP attorney Nancy Chiu Wilker, Ph.D., J.D., joins leadership team as vice president of legal Company also secured $15 million from Oxford Finance to further support pipeline development

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao , PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that b

PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce it has been issued a Medical Device Establishment License (“MDEL”) from Health Canada.

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the six months ended June 30, 2020 on Wednesday, September 23, 2020, and will host a conference call to

Production companies can qualify for 30 percent in tax credits using BioIQ’s COVID-19 testing solution to safely bring workers back and resume filming in Georgia. [16-September-2020] ATLANTA , Sept. 16, 2020 /PRNewswire/ -- BioIQ , an aggregator of testing solutions and optimizer of lab capacity for leading employers and health plans, announces that it is the first

Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance Presented Study on Long-Read Sequencing to Predict Phenotypic Antimicrobial Susceptibility Testing Results Work Aimed at Demonstrating Diagnostic Value of Next-Generation Sequencing for Antimicrobial Susceptibility Testing and Translation into Clinical Practice VIENNA, Austria and GAITHERSBURG, Md., Sept. 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today t

Pascal Biosciences Inc. (TSXV:PAS) oday Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in each of Pascal’s three cannabinoid programs. The title of his presentation is “Identifying and Validating Mechanism of Action In Vivo and In Vitro”.

- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted Biologics License Application (BLA) for NexoBrid ® (concentrate of proteolytic enzymes enriched in bromelain) for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of June 2

Investment in South Linden’s Rosewind community kicks-off the company’s nearly $600 million commitment to address racial inequality